INTRODUCTION: Fibrodysplasia ossificans progressiva (FOP) is characterized by progressive heterotopic ossification triggered by various conditions, such as trauma, infection, including COVID-19 infection, and vaccination. Although SARS-CoV-2 vaccinations prevent poor outcomes in the general population, there is limited evidence on safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines for inpatients with FOP. METHODS: A case series of two patients with FOP focused on humoral, cellular post-vaccination response, and the incidence of adverse events after administration of the BNT162b2 vaccine (Comirnaty). RESULTS: Injection site reactions, fever, myalgia, and fatigue were the most common adverse events (AE). Neither severe AE (SAE), nor disease flare-ups were observed. No differences between patients with FOP and healthy controls were observed in humoral and cellular responses. CONCLUSIONS: The BNT162b2 vaccine induced high humoral and cellular response levels in patients with FOP. Vaccination was not associated with SAE or disease relapse. The AEs spectrum was comparable to that of the general population.

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Paediatric and Adult Rheumatology Motol University Hospital Prague Czechia

Department of Virology Public Health Institute Ostrava Czechia

Zobrazit více v PubMed

Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. . A new coronavirus associated with human respiratory disease in China. Nature (2020) 579:265–9. doi: 10.1038/s41586-020-2008-3 PubMed DOI PMC

World Health Organization . WHO coronavirus (COVID-19) dashboard (2022). Available at: https://covid19.who.int/ (Accessed 6 March 2022).

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. . Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis (2020) 94:91–5. doi: 10.1016/j.ijid.2020.03.017 PubMed DOI PMC

Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. . Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PloS One (2021) 16:e0247461. doi: 10.1371/journal.pone.0247461 PubMed DOI PMC

Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the united states: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis (2021) 16:350. doi: 10.1186/s13023-021-01983-2 PubMed DOI PMC

Kaplan FS, Xu M, Glaser DL, Collins F, Connor M, Kitterman J, et al. . Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics (2008) 121:e1295–300. doi: 10.1542/peds.2007-1980 PubMed DOI PMC

Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, et al. . The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. a study of forty-four patients. J Bone Joint Surg Am (1993) 75:215–9. doi: 10.2106/00004623-199302000-00008 PubMed DOI

Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am (2010) 92:686–91. doi: 10.2106/JBJS.I.00705 PubMed DOI PMC

Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics (2005) 116:e654–61. doi: 10.1542/peds.2005-0469 PubMed DOI

Liu J-X, Hu R, Sun Y, Jiang H. General anesthesia in fibrodysplasia ossificans progressive: a case report and clinical review. Int J Clin Exp Med (2014) 7:1474–9. PubMed PMC

Grgurevic L, Novak R, Hrkac S, Salai G, Grazio S. Post-COVID-19 exacerbation of fibrodysplasia ossificans progressiva with multiple flare-ups and extensive heterotopic ossification in a 45-year-old female patient. Rheumatol Int (2021) 41:1495–501. doi: 10.1007/s00296-021-04911-6 PubMed DOI PMC

Brance ML, Cóccaro NM, Casalongue AN, Durán A, Brun LR. Extensive progressive heterotopic ossification post-Covid-19 in a man. Bone (2022) 155:116287. doi: 10.1016/j.bone.2021.116287 PubMed DOI PMC

Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. . Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav (2020) 4:1303–12. doi: 10.1038/s41562-020-01009-0 PubMed DOI

Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. . Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ (2021) 375:e068302. doi: 10.1136/bmj-2021-068302 PubMed DOI PMC

Kou S, Kile S, Kambampati SS, Brady EC, Wallace H, de Sousa CM, et al. . Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva. Res Sq (2021). doi: 10.21203/rs.3.rs-885603/v1 PubMed DOI PMC

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med (2021) 384:403–16. doi: 10.1056/NEJMoa2035389 PubMed DOI PMC

Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. . Efficacy and safety of NVX-CoV2373 in adults in the united states and Mexico. N Engl J Med (2022) 386:531–43. doi: 10.1056/NEJMoa2116185 PubMed DOI PMC

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577 PubMed DOI PMC

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, south Africa, and the UK. Lancet (2021) 397:99–111. doi: 10.1016/S0140-6736(20)32661-1 PubMed DOI PMC

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. . Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med (2021) 384:2187–201. doi: 10.1056/NEJMoa2101544 PubMed DOI PMC

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. . BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med (2021) 384:1412–23. doi: 10.1056/NEJMoa2101765 PubMed DOI PMC

Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. . Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg Health Am (2022) 6:100134. doi: 10.1016/j.lana.2021.100134 PubMed DOI PMC

Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty (2021) 10:132. doi: 10.1186/s40249-021-00915-3 PubMed DOI PMC

Milota T, Strizova Z, Smetanova J, Sediva A. An immunologist's perspective on anti-COVID-19 vaccines. Curr Opin Allergy Clin Immunol (2021) 21:545–52. doi: 10.1097/ACI.0000000000000788 PubMed DOI

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 61:344–9. doi: 10.1016/j.jclinepi.2007.11.008 PubMed DOI

de Ruiter RD, Smilde BJ, Pals G, Bravenboer N, Knaus P, Schoenmaker T, et al. . Fibrodysplasia ossificans progressiva: What have we achieved and where are we now? follow-up to the 2015 Lorentz workshop. Front Endocrinol (Lausanne) (2021) 12:732728. doi: 10.3389/fendo.2021.732728 PubMed DOI PMC

ICCFOP . Updated guidelines regarding coronavirus (COVID-19) to the FOP community (2022). Available at: http://www.iccfop.org/dvlp/wp-content/uploads/2021/03/Coronavirus-vaccination-FOP-031821-1.pdf (Accessed 6 March 2022).

Šimánek V, Pecen L, Krátká Z, Fürst T, Řezáčková H, Topolčan O, et al. . Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test. Diagn (Basel) (2021) 11:1–14. doi: 10.3390/diagnostics11040593 PubMed DOI PMC

Havlin J, Svorcova M, Dvorackova E, Lastovicka J, Lischke R, Kalina T, et al. . Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant (2021) 40:754–8. doi: 10.1016/j.healun.2021.05.004 PubMed DOI PMC

Smetanova J, Strizova Z, Sediva A, Milota T, Horvath R. Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol (2022) 4:e163–6. doi: 10.1016/S2665-9913(21)00393-3 PubMed DOI PMC

Piotto L, Taranath A. Fibrodysplasia ossificans progressiva: Diagnosis with ultrasound, australas. J Ultrasound Med (2021) 24:173–7. doi: 10.1002/ajum.12245 PubMed DOI PMC

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res (2011) 20:1727–36. doi: 10.1007/s11136-011-9903-x PubMed DOI PMC

Bruce B, Fries JF. The health assessment questionnaire (HAQ). Clin Exp Rheumatol (2005) 23:S14–8. PubMed

Scarlett RF, Rocke DM, Kantanie S, Patel JB, Shore EM, Kaplan FS. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res (2004) 423:275–9. doi: 10.1097/01.blo.0000129557.38803.26 PubMed DOI

Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, et al. . The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): A comprehensive global assessment. J Bone Miner Res (2016) 31:650–6. doi: 10.1002/jbmr.2728 PubMed DOI PMC

Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr (1995) 126:762–4. doi: 10.1016/s0022-3476(95)70408-6 PubMed DOI

Strizova Z, Smetanova J, Bartunkova J, Milota T. Principles and challenges in anti-COVID-19 vaccine development. Int Arch Allergy Immunol (2021) 182:339–49. doi: 10.1159/000514225 PubMed DOI PMC

Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. . Duration of protection against mild and severe disease by covid-19 vaccines. N Engl J Med (2022) 386:340–50. doi: 10.1056/NEJMoa2115481 PubMed DOI PMC

Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. . Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA (2021) 326:2043–54. doi: 10.1001/jama.2021.19499 PubMed DOI PMC

Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol (2022) 23:186–93. doi: 10.1038/s41590-021-01122-w PubMed DOI

Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature (2020) 584:457–62. doi: 10.1038/s41586-020-2550-z PubMed DOI

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. . Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med (2022) 386:1532–46. doi: 10.1056/NEJMoa2119451 PubMed DOI PMC

Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (2021) 398:2093–100. doi: 10.1016/S0140-6736(21)02249-2 PubMed DOI PMC

Risk M, Hayek SS, Schiopu E, Yuan L, Shen C, Shi X, et al. . COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol (2022) 4:775–84. doi: 10.1016/S2665-9913(22)00216-8 PubMed DOI PMC

Canaday DH, Oyebanji OA, White E, Keresztesy D, Payne M, Wilk D, et al. . COVID-19 vaccine booster dose needed to achieve omicron-specific neutralisation in nursing home residents. EBioMedicine (2022) 80:104066. doi: 10.1016/j.ebiom.2022.104066 PubMed DOI PMC

Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. . A bivalent omicron-containing booster vaccine against covid-19. N Engl J Med (2022) 387:1279–91. doi: 10.1056/NEJMoa2208343 PubMed DOI PMC

Hui DS. Hybrid immunity and strategies for COVID-19 vaccination. Lancet Infect Dis (2022) 1–2. doi: 10.1016/S1473-3099(22)00640-5 PubMed DOI PMC